Fusion Protein-Based Systems for Environmental Remediation

Publication ID: 24-11857601_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Fusion Protein-Based Systems for Environmental Remediation,” Published Technical Disclosure No. 24-11857601_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857601_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,601.

Summary of the Inventive Concept

The present inventive concept discloses novel applications of fusion protein technology, originally developed for cancer treatment, to address pressing environmental issues, such as industrial wastewater treatment, soil pollution remediation, and air quality monitoring.

Background and Problem Solved

The original patent disclosed a pharmaceutical composition for cancer treatment, comprising a fusion protein dimer including IL-2 and CD80 proteins, along with an anticancer drug. However, the environmental sector faces significant challenges in removing pollutants from wastewater, soil, and air, which the original patent did not address. The present inventive concept bridges this gap by applying the core fusion protein technology to develop innovative solutions for environmental remediation.

Detailed Description of the Inventive Concept

The new inventive concept encompasses systems, methods, and devices that utilize the fusion protein dimer, comprising IL-2 and CD80 proteins or their variants, to target and remove pollutants from wastewater, soil, and air. For instance, the system for treating industrial wastewater employs the fusion protein dimer to bind and neutralize pollutants, allowing for efficient removal and recycling of the treated water. Similarly, the method for reducing environmental pollutants in soil involves administering the pharmaceutical composition to the contaminated soil, where the fusion protein dimer facilitates the degradation of pollutants. The device for detecting water contaminants utilizes the fusion protein dimer as a biosensor to detect changes in the presence of pollutants, enabling real-time monitoring and swift response.

Novelty and Inventive Step

The new claims introduce a novel application of the fusion protein technology, shifting the focus from cancer treatment to environmental remediation. This inventive step lies in the recognition that the fusion protein dimer's binding properties can be leveraged to target and remove pollutants from various environmental sources, rather than solely for therapeutic purposes.

Alternative Embodiments and Variations

Alternative embodiments may include the use of different fusion protein dimers, varying the ratio of IL-2 to CD80 proteins, or incorporating additional components to enhance the system's efficiency. Variations may also involve adapting the system for specific types of pollutants or environmental matrices, such as oil spills or agricultural runoff.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the environmental sector, with applications in wastewater treatment, soil remediation, and air quality monitoring. The market for environmental remediation technologies is substantial, driven by increasing concerns over climate change, pollution, and public health. The fusion protein-based systems offer a unique, innovative solution that can be integrated into existing infrastructure, providing a competitive edge in the market.

CPC Classifications

SectionClassGroup
A A61 A61K38/2013
A A61 A61K31/337
A A61 A61K31/444
A A61 A61K31/4439
A A61 A61K31/47
A A61 A61K31/4709
A A61 A61K31/502
A A61 A61K31/506
A A61 A61K31/5025
A A61 A61K31/519
A A61 A61K31/708
A A61 A61K33/243
A A61 A61K38/1774
A A61 A61K39/3955
A A61 A61K45/06
A A61 A61P35/00

Original Patent Information

Patent NumberUS 11,857,601
TitlePharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
Assignee(s)GI Innovation, Inc.